Hyperforin Is A Key To St. John's Wort, Researchers Say

September 16, 1998

MOVANA™ Is Dietary Supplement With 50 Percent More Hyperforin

Ridgefield, CT--Sept. 16, 1998--Clinical research has shown what may be a key to St. John's Wort's power, a component called hyperforin, which is now widely available in the U.S. in an advanced extract of St. John's Wort found in a new product called MOVANA™, Pharmaton Natural Health Products announced today.

"This discovery is extremely exciting for people seeking a dependable route to a positive outlook on life," said Derrick DeSilva Jr., MD, a practicing internist who teaches at JFK Medical Center in Edison, NJ, and is author of Ask The Doctor: Herbs & Supplements for Better Health (Interweave Press 1997).

"While previous clinical studies have shown St. John's Wort is effective, questions remained about the identity of the active component and how it relates to efficacy. These studies on the extract in MOVANA™ help answer those questions."

The yellow-flowered plant with the Latin name Hypericum perforatum has been heralded for decades for its ability to balance emotions. More recently, scientists found it played a role in the transmission of brain signals through gaps in the nerve known as synapses. The transmission requires the release and then re-uptake of chemical bridges known as neurotransmitters. St. John's Wort was shown to inhibit the re-uptake of neurotransmitters such as serotonin (attributed to feelings of cheerfulness and calm, researchers say), noradrenaline (alertness and energy) and dopamine (sociability). By promoting normal levels of neurotransmitters, St. John's Wort helps maintain positive emotions.

The finding that hyperforin is one of the main active components of St. John's Wort is so significant that Pharmacopsychiatry, a prestigious German journal of clinical pharmacology and psychiatry, recently devoted an entire supplemental issue to hyperforin. It includes several recent clinical studies that show hyperforin may be the compound responsible for inhibiting neurotransmitter reuptake - rather than the compound hypericin as previously believed. One of the studies also shows that St. John's Wort with a higher hyperforin content is more effective.

In a randomized, double-blind placebo controlled study, published in Pharmacopsychiatry (June 1998), a group of 147 people took either a St. John's Wort extract with 5 percent hyperforin, one with 0.5 percent hyperforin or a placebo. At the end of the six-week trial, those taking the highest hyperforin dose showed the most positive results. Of those taking 5 percent hyperforin, 70 percent reported their condition was much or very much improved. That compares with 55 percent of those taking the 0.5 percent extract and 48 percent of those taking placebo.

Another study in the issue shows that a higher hyperforin content produces greater brain wave activity. In the double-blind, randomized, placebo-controlled parallel-group trial, 54 people took either placebo or St. John's Wort extracts with equal hypericin content but different hyperforin content (5 percent vs. 0.5 percent). After eight days, those who took the higher hyperforin showed the greatest changes in delta, theta and alpha-1 brain wave activity. Scientists hypothesize that this is physical evidence that hyperforin is inhibiting the re-uptake of seratonin, noradrenaline and dopamine.

Stabilization Breakthrough For Fragile Compound

Hyperforin is an extremely fragile compound that typically degrades rapidly. MOVANA™ employs a special patent-pending process to stabilize its hyperforin to a minimum of 3 percent - a full 50 percent higher than most other brands.

"With MOVANA™ you can be sure that when you want to maintain your sense of well-being, you are getting the help you expect each and every time," said Robert Carraher, executive director of marketing at Pharmaton Natural Health Products, a division of Boehringer Ingelheim Pharmaceuticals, Inc.

St. John's Wort has a strong record of safety and effectiveness in Europe where it has been popular for over 15 years and has been used with no serious side effects. The extract is made from the flowers and leaves of the plant, which blooms around June 24, the birthday of St. John the Baptist.

MOVANA™ is being marketed to adults who want to maintain a normal sense of well being, motivation and positive outlook on life even during times of stress and low-light seasons.

People who are taking a prescription medicine or pregnant or nursing women should speak with their physician before taking this or any other dietary supplement. Those with fair or sensitive skin who take this product should avoid prolonged direct sunlight or should use a sunscreen with an SPF of 15 or more, as photosensitivity may occur.

The mood support supplement is available in food, drug and mass merchandise outlets. The 300-mg tablets should be taken three times daily. Optimal effectiveness has been shown in as little as two weeks with continued use.

For additional information on MOVANA™, call 1 (877) 4-MOVANA (1 (877) 466-8262) or visit our website at http://www.movana.com.
-end-
Pharmaton Natural Health Products, of Ridgefield, CT, is committed to bringing safe, effective, standardized, clinically tested, dietary supplements to the U.S. marketplace. As a leader in the category, the company's mission is to enhance the reputation and growth of the natural health care industry as a whole. Part of that charge is to adhere to the guidelines set forth in the Dietary Supplement Health and Education Act (DSHEA) and to self-police the industry for unfair or misleading marketing tactics. Pharmaton Natural Health Products is the U.S. consumer products division of Boehringer Ingelheim

Pharmaceuticals, Inc. and is part of the Boehringer Ingelheim worldwide group of companies, based in Ingelheim-on-the-Rhine, Germany. Boehringer Ingelheim is a major pharmaceutical, chemical and animal health company with operations in 160 countries around the world. Currently, its GINKOBA and GINSANA brands are among the top-selling brands in the United States.

Contact:
Barbara Goldberg
Creamer Dickson Basford
(212) 367-6849 (o)
(212) 595-4977 (h)

James Heins
For Pharmaton
Natural Health Products
(203) 798-4715

Editor's Note: Product photography available upon request.

The statements presented here have not been evaluated by the Food and Drug Administration. MOVANA™ is not intended to diagnose, treat, cure or prevent any disease.
-end-


Creamer Dickson Basford

Related Placebo Articles from Brightsurf:

Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19
This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.

Hydroxychloroquine no more effective than placebo in preventing COVID-19
Clinical trial with COVID-19 testing of participants shows health care workers in contact with coronavirus patients who took hydroxychloroquine each day did not reduce their rate of infection.

Compared to placebo, vitamin D has no benefit for severe asthma attacks
Contrary to earlier observational results, vitamin D supplements do not prevent severe asthma attacks in at-risk children, according to the first placebo-controlled clinical trial to test this relationship.

UMN trial shows hydroxychloroquine has no benefit over placebo in preventing COVID-19
Today, University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the post-exposure prevention of COVID-19.

The placebo effect and psychedelic drugs: tripping on nothing?
A new study from McGill suggests that, in the right context, some people may experience psychedelic-like effects from placebos alone.

Methotrexate reduces joint damage progression over placebo in erosive hand OA
According to new research findings presented at the 2019 ACR/ARP Annual Meeting, methotrexate did not demonstrate superior efficacy over placebo for pain relief and function evolution at three and 12 months in patients with erosive hand osteoarthritis, but did significantly reduce the progression of joint damage over placebo and seems to facilitate bone remodeling in these patients.

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.

Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.

Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.

Read More: Placebo News and Placebo Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.